Antibody for Binding to Interleukin 4 Receptor
Summary
USPTO granted Patent US12600771B2 to Connect Biopharma Hong Kong Limited for an antibody capable of binding to the interleukin 4 (IL-4) receptor. The patent covers the antibody itself, encoding nucleic acids, vectors, host cells, production methods, medical uses, and kits. The patent contains 30 claims and was filed on November 15, 2023.
What changed
USPTO granted patent US12600771B2 to Connect Biopharma Hong Kong Limited for an antibody targeting the interleukin 4 receptor (IL-4R). The patent encompasses the antibody structure, encoding nucleic acid sequences, expression vectors, transformed host cells, production methods, medical applications, and diagnostic kits incorporating the antibody. The invention is classified under CPC codes A61K 39/395, C07K 14/7155, and C07K 16/2866, indicating therapeutic protein and antibody technologies.
For pharmaceutical and biotechnology companies developing IL-4 pathway-targeted therapies, this patent establishes intellectual property barriers. Competitors working on IL-4R antagonists, dupilumab biosimilars, or other IL-4/IL-13 pathway biologics should evaluate freedom-to-operate implications. The broad claim scope covering methods of treatment may restrict generic or biosimilar development in this therapeutic space.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibody for binding to interleukin 4 receptor
Grant US12600771B2 Kind: B2 Apr 14, 2026
Assignee
CONNECT BIOPHARMA HONGKONG LIMITED
Inventors
Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
Abstract
Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
CPC Classifications
A61K 39/395 A61K 2039/505 C07K 14/7155 C07K 2317/76 C07K 16/2866 C07K 2317/565
Filing Date
2023-11-15
Application No.
18510553
Claims
30
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.